Garon et al., 2023 [52] reported that baseline alterations in ctDNA were prognostic indicators in patients with metastatic NSCLC harboring active EGFR mutations, with improvements in PFS observed when treated with ramucirumab plus erlotinib. Here, EGFR is linked to non-small cell lung carcinoma.